Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis in Refractory Macular Edema Due to Eales' Disease
NCT00384449Phase 3Completed
- Sponsor
- Oregon Health & Science University
- Start
- Oct 2006
- Primary completion
- Apr 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in Eales disease (ED), sponsored by Oregon Health & Science University. Primary endpoints: Change in OCT Thickness at 6 months, Incidence and Severity of Ocular Adverse Events and 1 more. Started Oct 2006; status: completed.
02
Drugs
ranibizumab
03
Conditions
Eales disease (ED)
Beyond the preview
Go deeper on NCT00384449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384449.